Enanta Pharmaceuticals Inc(ENTA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:25 PM ET (Korea 10/30 05:25)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.41 | Insider Own | 4.74% | Shs Outstand | 29.1M | Perf Week | -4.04% |
| Market Cap | 0.32B | Forward P/E | - | EPS next Y | 4.13% | Insider Trans | - | Shs Float | 27.8M | Perf Month | -15.4% |
| Enterprise Value | 0.32B | PEG | - | EPS next Q | -0.72 | Inst Own | 94.12% | Short Float | 8.16% | Perf Quarter | -11.51% |
| Income | -0.06B | P/S | 4.98 | EPS this Y | 40.29% | Inst Trans | 3.71% | Short Ratio | 9.25 | Perf Half Y | -19.73% |
| Sales | 0.07B | P/B | 3.21 | EPS next 5Y | 11.43% | ROA | -21.15% | Short Interest | 2.27M | Perf YTD | -29.3% |
| Book/sh | 3.47 | P/C | 1.71 | EPS past 3/5Y | 13.4% -16.17% | ROE | -70.12% | 52W High | -34.99% ($17.15) | Perf Year | 4.89% |
| Cash/sh | 6.51 | P/FCF | - | Sales past 3/5Y | -8.82% -11.81% | ROIC | -26.08% | 52W Low | 9.1% ($10.22) | Perf 3Y | 33.53% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 44.24% | Gross Margin | 92.48% | Volatility(W/M) | 5.87% 5.49% | Perf 5Y | -87.01% |
| Dividend TTM | - | EV/Sales | 4.86 | Sales Y/Y TTM | 0.7% | Oper. Margin | -89.99% | ATR (14) | 0.68 | Perf 10Y | -53.41% |
| Dividend Ex-Date | - | Quick Ratio | 3.76 | EPS Q/Q | 21.5% | Profit Margin | -96.89% | RSI (14) | 40.41 | Recom | 1.17 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.76 | Sales Q/Q | -21.6% | SMA20 | -5.83% ($11.84) | Beta | 0.72 | Target Price | $21.83 |
| Payout | - | Debt/Eq | 1.8 | Earnings | 2026/8/10 | SMA50 | -11.37% ($12.58) | Rel Volume | 0.89 | Prev Close | $11.55 |
| Employees | 120 | LT Debt/Eq | 1.4 | EPS/Sales Surpr. | -31.5% -14.34% | SMA200 | -15.6% ($13.21) | Avg Volume(3M) | 0.24M | Price | $11.15 |
| IPO | 2013/3/21 | Option/Short | Yes/Yes | Trades | 2568 | Volume | 218,315 | Change | -3.46% |
A US clinical-stage biotech company focused on antiviral therapeutics for respiratory syncytial virus (RSV). Leveraging its proprietary chemistry platform, it develops oral antiviral treatments as well as candidates for immune and liver diseases, maintaining a leading pipeline in the respiratory virus therapeutics space that is differentiated from preventive vaccines.
Over the past 1 year, on the lower side
35% below its 1-year high.
Traded about as much as usual. That is 89% of its average volume.
ENTA has a sound balance sheet but weak earning power
Of every $100 in sales, $89.99 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +40.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $498. Peers typically go for $1,217.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -87.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 94.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
QQQS Invesco NASDAQ Future Gen 200 ETF <0.01% 
DWAS Invesco Dorsey Wright SmallCap Momentum ETF <0.01% 
FSML Franklin Small Cap Enhanced ETF <0.01% 
IWC iShares Micro-Cap ETF <0.01% 
FSEV Fidelity Enhanced Small Cap Value ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
VXF Vanguard Extended Market Index ETF 30.5B 
FNDX Schwab Fundamental U.S. Large Company ETF 28.4B 
FNDF Schwab Fundamental International Equity ETF 25.7B 
DGRW WisdomTree U.S. Quality Dividend Growth Fund 17.0B 
HDV iShares Core High Dividend ETF 15.8B It ranks #261 of 594 in the industry
Based on market cap of $325M.
SCTX#258 Scribe Therapeutics Inc $330M PER - 
TTRX#259 Turn Therapeutics Inc $327M PER - 
PRLD#260 Prelude Therapeutics Inc $327M PER - ENTA#261 Enanta Pharmaceuticals Inc $325M PER - 
AGEN#262 Agenus Inc $320M PER 2.7 
FAQ
What kind of company is ENTA?
ENTA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ENTA?
The market cap of ENTA is approximately $325M, ranking 3,569 within its sector.
What is the 52-week high and low for ENTA?
ENTA has recorded a 52-week high of $17.15 and a low of $10.22.
